# 2025-16245: FDA Hosts Chat on Hiring for Speedier Drug Approvals

2025-16245, Prescription Drug User Fee Act and Biosimilar User Fee Amendments Hiring and Retention Assessment; Public Meeting; Request for Comments, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-08-25 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-16245
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-16245
- Title: Prescription Drug User Fee Act and Biosimilar User Fee Amendments Hiring and Retention Assessment; Public Meeting; Request for Comments
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 41395
- Published: 2025-08-25
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Hosts Chat on Hiring for Speedier Drug Approvals

## Summary

The FDA is hosting a public meeting to talk about how well they’re hiring and keeping staff who work on drug and biosimilar fees. This check-up helps make sure the agency can keep up with reviewing new medicines quickly. If you’re involved in drug development or just curious, now’s the time to share your thoughts and help shape the future!

## Abstract

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Prescription Drug User Fee Act and Biosimilar User Fee Amendments Hiring and Retention Assessment." The topic to be discussed is a hiring and retention assessment which was performed by an independent contractor.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-16245 on federalregister.gov](https://www.federalregister.gov/documents/2025/08/25/2025-16245/prescription-drug-user-fee-act-and-biosimilar-user-fee-amendments-hiring-and-retention-assessment)
- [2025-16245 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-08-25/pdf/2025-16245.pdf)

## Related
- [Previous: 2025-16243, 60-Day Notice of Proposed Information Collection: Nontransfer and Use Certifica…](https://policyrisk.com/federal-register/2025-16243)
- [Next: 2025-16247, Notice of Public Meeting of the District of Columbia Advisory Committee; Revisi…](https://policyrisk.com/federal-register/2025-16247)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-16245 (as of 2026-06-08).
